← Back to Search

NMDA Receptor Antagonist

Ketamine for Depression (K-PASS Trial)

Phase 3

Waitlist Available

Research Sponsored by Washington University School of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 days after intervention

Awards & highlights

K-PASS Trial Summary

This trial will test whether a low dose of ketamine can prevent postoperative depression in neurosurgical patients with a history of depression.

Eligible Conditions

Postoperative Depression

K-PASS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 days after intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 days after intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 days after intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Fraction of Approached Patients Who Enroll and Are Randomized

Fraction of Randomized Patients Who Complete the Study Infusion

Fraction of Randomized Patients With Depression Rating Scale Scores at All Specified Time Points

Secondary outcome measures

Delta Sleep Ratio on Night 1 Following Study Medication

Depressive Symptoms on Day 4

K-PASS Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Ketamine ArmExperimental Treatment1 Intervention

Following surgery and extubation, patients will receive ketamine 0.5 mg/kg over 10 minutes followed by an infusion of 0.3 mg/kg/h for 2 hours 50 minutes.

Group II: Control ArmPlacebo Group1 Intervention

Following surgery and extubation, patients will receive normal saline at an equal rate to that used in the ketamine arm.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ketamine

2011

Completed Phase 4

~1090

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor

1,933 Previous Clinical Trials

2,299,693 Total Patients Enrolled

68 Trials studying Depression

23,347 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When will Ketamine be available for general prescription use?

"There is a fair amount of clinical evidence affirming Ketamine's safety, as it is a Phase 3 trial medication."

Answered by AI

Are people with the specified illnesses still able to join this research project?

"Yes, according to the latest update on clinicaltrials.gov, this trial is still looking for enrollees. The study was first posted on April 25th, 2022 and was last updated on September 21st, 2022. They are specifically looking for 32 patients at a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial

Bradley Fritz 2022. "Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05233566.